Sign inJoin waitlistJoin the waitlist

Saakshi Khattri

Director of the Dermatology/Rheumatology Service · Mount Sinai

Credentials: · · · · · ·

History

Icahn School of Medicine at Mount Sinai
Present
Icahn School of Medicine at Mount Sinai
Present

Rockefeller University
2013–2014
Rheumatology
Montefiore Medical Center/Albert Einstein College of Medicine
2010–2012
Dermatology
Icahn School of Medicine at Mount Sinai
Chief Resident
2007–2010
Internal Medicine
Staten Island University Hospital
2007–2010
Preliminary or Transitional Year
2006–2007
Maulana Azad Medical College
2002–2006

Research

Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A…
Journal of the American Academy of Dermatology · 2018 · 270 citations
The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins
Scientific Reports · 2017 · 221 citations
Severe atopic dermatitis is characterized by selective expansion of circulating TH2/TC2 and TH22/TC22, but not TH17/TC17, cells within the skin-homing T-cell population
Journal of Allergy and Clinical Immunology · 2015 · 191 citations

Emma Guttman
14 papers
JK
James Krueger
12 papers
Alice Gottlieb
9 papers
Mark Lebwohl
9 papers
MH
Mary Hren
8 papers · 2 as a resident
April Armstrong
7 papers
Joseph Merola
6 papers
Patrick Brunner
6 papers
RF
Robert Finney
5 papers · 4 as a resident
Tali Czarnowicki
4 papers
Xuan Li
4 papers
AC
Ahuva Cices
3 papers · 3 as a fellow

Clinical trials

Spesolimab in Pyoderma Gangrenosum
Principal investigator · Terminated · Phase 2
Icahn School of Medicine at Mount Sinai
2023–2025
A Study to Evaluate the Efficacy and Safety of Secukinumab in Adult Patients With Skin Types IV-VI With Moderate to Severe Plaque Psoriasis
Principal investigator · Completed · Phase 4
Saakshi Khattri
2019–2022
Aczone Gel 7.5% in the Treatment of Acne Vulgaris in Patients With Skin of Color
Principal investigator · Completed · Phase 4
Icahn School of Medicine at Mount Sinai
2019–2021
Apremilast in the Treatment of Central Centrifugal Cicatricial Alopecia (CCCA)
Principal investigator · Completed · Phase 4
Icahn School of Medicine at Mount Sinai
2018–2021